The potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 800-806

  Luther, Neal ^a   Zhou, Zhiping ^a   Zanzonico, Pat ^b   Cheung, Nai Kong ^b   Humm, John ^b   Edgar, Mark A ^c   Souweidane, Mark M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody; brain stem; glioma; interstitial; PET; radioimmunotherapy

Indexed keywords

IODINE 124; IODINE 131; 8H9 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN STEM; CAPSULA INTERNA; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOSIMETRY; DRUG SAFETY; HEMIPARESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE COMPLICATION; PONS; PONTINE GLIOMA; POSITRON EMISSION TOMOGRAPHY; PRECENTRAL SULCUS; RADIATION INJURY; RADIATION SAFETY; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RAT; WEIGHT REDUCTION; WOUND DEHISCENCE; WOUND INFECTION; ANIMAL; BRAIN STEM NEOPLASMS; GLIOMA; HUMAN; MACACA FASCICULARIS; MALE; RADIOMETRY; SCINTISCANNING; THERMODYNAMICS;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN STEM NEOPLASMS; CONVECTION; GLIOMA; HUMANS; IODINE RADIOISOTOPES; MACACA FASCICULARIS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOMETRY; RATS;

EID: 84901021442     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not298     Document Type: Article

References (44)

1. Kaplan AM, Albright AL, Zimmerman RA, et al. Brainstem gliomas in children: a Children's Cancer Group review of 119 cases. Pediatr Neurosurg. 1996;24(4):185-192.
2. Cohen ME, Duffner PK. Brain Stem Tumors. Brain Tumors in Children: Principles of Diagnosis and Treatment, 2nd edn. New York: Raven Press; 1994: 241-262.
3. Dunkel IJ, Garvin JH Jr., Goldman S, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neurooncol. 1998;37(1):67-73.
4. Dunkel IJ, O'Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosurg. 1996;24(5):263-266.
5. Frazier JL, Lee J, ThomaleUW, Noggle JC, Cohen KJ, Jallo GI. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009;3(4):259-269.
6. Bernier-ChastagnerV, Grill J,Doz F, et al. Topotecan asaradiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology phase II study. Cancer. 2005;104(12):2792-2797.
7. Korones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer. 2008;50(2):227-230.
8. Freeman CR, Krischer JP, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys. 1993;27(2):197-206.
9. Walter AW, Gajjar A, Ochs JS, et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol. 1998; 30(1):28-33.
10. Sanghavi SN, NeedleMN,KrailoMD,Geyer JR, Ater J,MehtaMP.Aphase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952. Neuro Oncol. 2003;5(1):8-13.
11. Finlay JL, ZacharoulisS. Thetreatmentof highgradegliomasanddiffuse intrinsic pontine tumors of childhood and adolescence: a historical-and futuristic-perspective. J Neurooncol. 2005;75(3):253-266.
12. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241-248.
13. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994;266(1 Pt 2):R292-R305.
14. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery to macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91(6):2076-2080.
15. Groothuis DR, Ward S, Itskovich AC, et al. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convectionenhanced intracerebral infusion. J Neurosurg. 1999;90(2):321-331.
16. Laske DW,Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg. 1997;87(4):586-594.
17. Sandberg DI, Edgar MA, Souweidane MM. Convection-enhanced delivery into the rat brain stem. J Neurosurg. 2002;96(5):885-891.
18. Luther N, Cheung NK, Dunkel IJ, et al. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. Neurosurgery. 2008;63(6):1166-1174.
19. Lonser RR,WarrenKE,ButmanJA, et al.Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg. 2007;107(1):190-197.
20. Occhiogrosso G, Edgar MA, Sandberg DI, Souweidane MM. Prolonged convection enhanced delivery into the rat brain stem. Neurosurg. 2003;52(2):388-393.
21. Modak S, Kramer K, Gultekin S, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001;61(10): 4048-4054.
22. Luther N, Cheung NK, Souliopoulos EP, et al. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther. 2011;10(4):708.
23. Asthagiri AR, Walbridge S, Heiss JD, Lonser RR. Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. J Neurosurg. 2011; 115(3):467-473.
24. Croteau D,Walbridge S, Morrison PF, et al. Real-time in vivo imaging of the convecive distribution of a low-molecular-weight tracer. J Neurosurg. 2005;102(1):90-97.
25. Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409-418.
26. Murad GJ, Walbridge S, Morrison PF, et al. Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res. 2006;12(10):3145-3151.
27. Bumb A, Brechbiel MW, Choyke P. Macromolecular and dendrimerbased magnetic resonance contrast agents. Acta radiologica. 2010; 51(7):751-767.
28. Souweidane MM, Occhiogrosso G, Mark EB, Edgar MA, Dunkel IJ. Interstitial infusion of carmustine in the rat brainstem with systemic administration of O6-benzylguanine. J Neurooncol. 2004;67(3): 305-317.
29. Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg. 2002;97(4):905-913.
30. Krauze MT, Vandenberg SR, Yamashita Y, et al. Safety of real-time convection-enhanced delivery of liposomes to primate brain: a longterm retrospective. Experimental Neurology. 2008;210(2):638-644.
31. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioms: a phase I/II clinical study. J Neurosurg. 2004;100(3):472-479.
32. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003; 65(1):27-35.
33. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004;68(1):1-9.
34. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 2006;8(3): 205-214.
35. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl. 2003; 88:105-111.
36. Prados M, Lang FF, Sherman JW, et al. Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and pretumoral administration of IL13-PE38QQR a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. Neuro Oncol. 2002;4(Suppl 1):S78.
37. Vogelbaum MA, Sampson JH, Kunwar S, et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery. 2007;61(5):1031-1037; discussion 1037-1038.
38. Kunwar S,ChangS,Westphal M, et al. Phase III randomizedtrial ofCED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12(8):871-881.
39. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010;113(2):301-309.
40. Mueller S, Polley MY, Lee B, et al. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol. 2011;101(2):267-277.
41. Jagannathan J,Walbridge S, Butman JA, Oldfield EH, Lonser RR. Effect of ependymal and pial surfaces on convection-enhanced delivery. J Neurosurg. 2008;109(3):547-552.
42. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurg. 1996;38(4):746-754.
43. Cunningham J, Oiwa Y, Nagy N, Podsakoff G, Colosi P, Bankiewicz KS. Distribution of AAV-TK following intracranial convectionenhanced delivery into rats. Cell Transplant. 2000;9(5):585-594.
44. Kramer K, Cheung NK, Humm J, et al. Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. J Neurooncol. 1997; 35(2):101-111.